Last reviewed · How we verify
Candidal Urinary Tract Infection — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Diflucan | fluconazole | Pfizer Inc. | Azole Antifungal [EPC] | Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase | 1990-01-29 | |
| Ancobon | FLUCYTOSINE | Bausch Health | Nucleoside Analog Antifungal [EPC] | 5-hydroxytryptamine receptor 2A | 1971-01-01 | |
| Fluconazol | Fluconazol | Azienda Sanitaria-Universitaria Integrata di Udine | Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Azienda Sanitaria-Universitaria Integrata di Udine · 1 drug in Candidal Urinary Tract Infection
- Bausch Health · 1 drug in Candidal Urinary Tract Infection
- Pfizer Inc. · 1 drug in Candidal Urinary Tract Infection
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Candidal Urinary Tract Infection:
- Candidal Urinary Tract Infection treatment updates — RSS
- Candidal Urinary Tract Infection treatment updates — Atom
- Candidal Urinary Tract Infection treatment updates — JSON
Cite this brief
Drug Landscape (2026). Candidal Urinary Tract Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/candidal-urinary-tract-infection. Accessed 2026-06-10.
Related
- Candidal Urinary Tract Infection full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing